DYSTROGEN THERAPEUTICS

# Dystrogen Therapeutics Granted U.S. Patent for Myoblast Chimeric Cell Therapy

## USPTO Grants Patent US20220160783A1 Covering Breakthrough Cell Therapy Platform for Muscular Dystrophy and Muscle-Wasting Disorders

May 27, 2025

Dystrogen Therapeutics is proud to announce that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. US20220160783A1, covering the company's innovative Myoblast Chimeric Cells (MCCs) platform.

This patented method represents a transformative approach to muscle regeneration through the ex vivo fusion of myoblasts from healthy donors with myoblasts derived from patients suffering from muscular dystrophies. The resulting chimeric cells combine the regenerative capabilities of donor cells with the immunological compatibility of autologous cells.

Key advantages of this novel platform include:

- Broad Therapeutic Applicability – The technology is mutation-agnostic, positioning it for use across a wide spectrum of muscular dystrophies, including Duchenne muscular dystrophy (DMD).

- Reduced Immunogenicity – By incorporating patient-derived cells, the chimeric therapy avoids typical immune rejection challenges associated with allogeneic cell therapies.

- Functional Recovery – Preclinical studies have demonstrated enhanced dystrophin expression and improved muscle regeneration.

- Future Applications – This patent forms the foundation for further development in muscle-wasting disorders such as sarcopenia, cancer cachexia, and age-related degeneration.

"This patent solidifies our leadership in the field of cell-based regenerative medicine for muscle disorders," said [Spokesperson Name], [Title] at Dystrogen Therapeutics. "It is an important milestone in our mission to deliver transformative therapies to patients who currently have few or no treatment options."

For more information, visit: https://patents.google.com/patent/US20220160783A1

Media Contact:

[Name]

DYSTROGEN
THERAPEUTICS

[Title]

[Email]

[Phone]